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Abstract
Objective
To perform a systematic review and meta-analysis of randomized controlled trials (RCTs)
examining the eﬀectiveness of continuous positive airway pressure (CPAP) in stroke patients
with sleep disordered breathing (SDB).
Methods
In a systematic literature search of electronic databases (MEDLINE, Embase, and the Cochrane
Library) from 1980 to November 2016, we identiﬁed RCTs that assessed CPAP compared to
standard care or sham CPAP in adult patients with stroke or TIA with SDB. Mean CPAP use,
odds ratios (ORs), and standardized mean diﬀerences (SMDs) were calculated. The pre-
speciﬁed outcomes were adherence to CPAP, neurologic improvement, adverse events, new
vascular events, and death.
Results
Ten RCTs (564 participants) with CPAP as intervention were included. Two studies compared
CPAP with sham CPAP; 8 compared CPAP with usual care. Mean CPAP use across the trials
was 4.53 hours per night (95% conﬁdence interval [CI] 3.97–5.08). The OR of dropping out
with CPAP was 1.83 (95% CI 1.05–3.21, p = 0.033). The combined analysis of the neuro-
functional scales (NIH Stroke Scale and Canadian Neurological Scale) showed an overall
neurofunctional improvement with CPAP (SMD 0.5406, 95% CI 0.0263–1.0548) but with
a considerable heterogeneity (I2 = 78.9%, p = 0.0394) across the studies. Long-term survival
was improved with CPAP in 1 trial.
Conclusion
CPAP use after stroke is acceptable once the treatment is tolerated. The data indicate that
CPAP might be beneﬁcial for neurologic recovery, which justiﬁes larger RCTs.
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Sleep disordered breathing (SDB) with an apnea-hypopnea in-
dex (AHI) >15/h is present in ≈26% of the general population
and a common comorbidity in stroke survivors.1–3 The reported
prevalence after stroke varies between 50% and 70%, depending
on the chosen cutoﬀ for the AHI and time lag from stroke, but it
is consistently higher in acute stroke patients than in the general
population.4,5 SDB can improve after the acute stroke phase, but
up to 60% of the patients still show an AHI >10/h and 30% show
anAHI>30/h≈3months after the stroke orTIA.1,2,4Most of the
stroke patients have obstructive sleep apnea (OSA), which has
been identiﬁed as an independent risk factor for stroke and is
associated with a higher mortality.6–9
Treatment of OSA with continuous positive airway pressure
(CPAP) leads to improvements in sleepiness and cognitive
performance in the general population, but the data on the
prevention of cardiovascular or cerebrovascular disease10–13
and its eﬀects on neurologic recovery after stroke14 are still
conﬂicting. Identifying and treating OSA in stroke survivors
was added to the American Heart Association/American
Stroke Association stroke guidelines in 2014 with a Class IIb
recommendation and Level of Evidence B.15 However, the
timing of diagnostic investigations and treatment initiation has
not been speciﬁed, and unlike other independent risk factors
for stroke, e.g., arterial hypertension or dyslipidemia, which are
usually identiﬁed and treated in stroke patients within the ﬁrst
days after hospital admission, the treatment of SDB is still often
neglected.16 Concerns include the feasibility and eﬀectiveness
of CPAP in the acute setting, which might partially explain the
large number of undiagnosed and untreated patients and delays
between admission for stroke and start of OSA treatment.4,17
In addition to nonrandomized observational studies withmatched
control groups, more randomized controlled trials (RCTs) using
CPAP have been published recently in stroke cohorts. Thus, the
objective of the present study was to systematically review and
analyze the literature on treatment of SDB in adult patients after
TIA or stroke with regard to acceptance of CPAP and its eﬀec-
tiveness to modify clinical outcome parameters.
Methods
This systematic review and meta-analysis is reported accord-
ing to the PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines.18
Search strategy
We performed a systematic search of MEDLINE, Embase,
and the Cochrane Library between January 1980 and
November 2016 to identify RCTs comparing CPAP with
sham CPAP or usual care to treat SDB in adult patients after
a TIA or stroke. The full list of search terms is included in
tables e-1 through e-3 (links.lww.com/WNL/A320). To
identify additional trials, we examined reference lists of the
identiﬁed articles, relevant reviews in the ﬁeld, and clinical trial
registries.
Study selection
Study selection was performed in duplicate by 2 independent
authors (A.-K.B.,T.H.). Disagreement was resolved by dis-
cussion with a third author (A.S.). The titles and abstracts of
identiﬁed publications were screened, and potentially relevant
articles were retrieved for a full-text review. A full list of in-
clusion and exclusion criteria is given in table e-4 (links.lww.
com/WNL/A320). In short, inclusion was restricted to full-
text RCTs comparing CPAP with shamCPAP or usual care to
treat SDB in adult patients after a stroke or TIA. There were
no language restrictions. We excluded duplicate publications,
all study designs other than RCTs, abstracts, conference
communications, and other interventions to treat SDB.
Data extraction
The prespeciﬁed outcomes for the meta-analysis were nightly
use (adherence), reduction of AHI compared to baseline;
dropouts; improvement of the NIH Stroke Scale (NIHSS),
Canadian Neurological Scale (CNS), or other neurofunc-
tional and cognitive parameters19; adverse events related to
the intervention; new vascular events; and mortality (table
e-4, links.lww.com/WNL/A320). If multiple reports were
available for 1 trial, we used information of all reports for data
extraction but extracted outcome data only once on the basis
of completeness and follow-up.
All data were extracted independently and in duplicate (A.-K.B.,
T.H.) for each included RCT with a standardized prespeciﬁed
data collection form. If multiple follow-up time points were
present, the longest follow-up was considered. Studies were
divided into early treatment, deﬁned as treatment onset within
7 days after a cerebrovascular event, and delayed treatment,
starting >7 days after TIA or stroke. We contacted the authors
of all RCTs to obtain additional individual patient data on
neurologic outcomes.
Assessment of risk of bias
The quality of each included RCT was assessed with the
Cochrane risk of bias tool, which covers 6 domains of bias:
selection bias, performance bias, detection bias, attrition bias,
reporting bias, and other bias.20 For each RCT, 2 reviewers
(A.-K.B., T.H.) independently assigned a score of high, low, or
Glossary
AHI = apnea-hypopnea index; CI = conﬁdence interval; CNS = Canadian Neurological Scale; CPAP = continuous positive
airway pressure; NIHSS = NIH Stroke Scale; OSA = obstructive sleep apnea; PRISMA = Preferred Reporting Items for
Systematic Reviews and Meta-Analyses; RCT = randomized controlled trial; SDB = sleep disordered breathing.
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unclear quality for each domain. Disagreement was resolved
by discussion with a third author (M.C.).
Statistical analysis
Mean CPAP use per night (compliance), odds ratios of
dropping out of the trial, and standardized mean diﬀerences
(expressed as the Hedge g) in NIHSS and CNS scores were
combined in DerSimonian-Laird random-eﬀects meta-
analysis. Heterogeneity was assessed with I2 statistics, with
I2 values of >50% considered as substantial heterogeneity and
I2 >75% as considerable heterogeneity.21 We intended to
assess publication bias using funnel plot techniques, the Begg
rank test, and the Egger regression test, as appropriate. We
used the meta package in R (version 3.3.2; R Foundation for
Statistical Computing, Vienna, Austria) for all analyses.22,23
Results are presented as estimates with 95% conﬁdence
intervals (CIs).
Results
Search results
From 2,880 publications that were retrieved by the literature
search, we identiﬁed 27 studies (30 full-text publications) with
interventions to treat SDB after TIA or stroke (ﬁgure 1 and
table e-5, links.lww.com/WNL/A320). Ten studies were
RCTs using CPAP to treat OSA to improve post-TIA or
poststroke outcomes in adults and were included in the meta-
analysis (table 1).
Study characteristics
The included RCTs that randomized a total of 564 partic-
ipants with TIA or clinically or imaging-conﬁrmed stroke.
Four RCTs provided information on stroke subtypes
according to the etiology or the vascular territory24–27; 1 RCT
diﬀerentiated between hemorrhagic and ischemic stroke.28 In
7 RCTs, prediagnosed or already treated SDB was an exclu-
sion criterion. The other 3 studies did not provide in-
formation on preexisting SDB.25,29,30 Mean baseline AHI
ranged from 11/h to 38.5/h and depended on the study-
speciﬁc inclusion criteria (table e-5, links.lww.com/WNL/
A320).26,31 Three studies did not assess AHI at inclusion
because of immediate initiation of CPAP and a delayed per-
formance of the diagnostic polysomnography.25,32,33 Studies
were performed in acute care hospitals or in rehabilitation
units with study durations and follow-ups varying between 8
days and 5 years. The sample size varied between 30 and 140
participants.
In 5 trials, treatment was started early within 7 days after
stroke. The other 5 studies initiated treatment 10 to 28 days
after the cerebrovascular event (table e-5, links.lww.com/
WNL/A320). Details of the individual study characteristics
are provided in table 1 and table e-5.
Assessment of risk of bias
The individual risk of bias in the 10 RCTs was mixed with
an overall high risk of bias for blinding of participants in
the open-label studies and a lower risk in the more recent
trials (table e-6, links.lww.com/WNL/A320).24,28,31
Publication bias was not assessed because there were in-
adequate numbers of included trials to properly assess
a funnel plot or more advanced regression-based
assessments.
Reduction of AHI, dropouts, and compliance
Information on the reduction of AHI with CPAP was repor-
ted in 3 studies and reached a mean AHI of <10/h.24–26
Dropouts and adherence to CPAP were evaluated in all trials.
Dropout rates ranged from 0% to 46%, with more dropouts in
the CPAP groups than for sham CPAP or usual care. There
were more dropouts in the trials starting CPAP early. The
combined odds ratio of dropping out was 1.83 (95% CI
1.05–3.21, p = 0.033) with no between-study heterogeneity
(I2 = 0%) (ﬁgure 2).
Seven RCTs reported a mean CPAP use of ≥4 hours
a night, and 2 had a mean CPAP use <4 hours a night,
resulting in a combined mean CPAP use of 4.53 hours
a night (95% CI 3.97–5.08), but with considerable het-
erogeneity (I2 = 87.2%, p < 0.0001) across the studies
(ﬁgure 3 and table 1). CPAP use and heterogeneity were
similar in the subgroup analysis (p = 0.0631, early CPAP I2
= 84.0%, delayed CPAP I2 = 84.2%). One study with
a reported low adherence could not be included in the
meta-analysis because of insuﬃcient data in the publication
and no reply from the authors.29
Factors associated with poor adherence were neurologic im-
pairment, mask discomfort, depressive symptoms, or sub-
jective sleep disturbance.29,30 None of the RCTs assessed
a potential association between excessive daytime sleepiness
or preexisting SDB and subsequent CPAP use.
Adverse events
Four RCTs reported details on adverse events.26,27,32,33 Se-
rious adverse events not related to the study intervention were
mentioned in the 2 studies without diﬀerences between
CPAP and controls (patients with TIA: CPAP, 7 events in 45
participants [15.6%], and controls, 4 events in 25 participants
[16%]; stroke patients: CPAP, 2 events in 31 patients [6.5%],
and controls, 5 events in 24 participants [20.8%]).32,33 There
were no serious adverse events related to CPAP. Nonserious
adverse events were more frequent in the CPAP groups and
were related mainly to the mask (e.g., facial marks or dry
noses).32,33
Neurofunctional outcomes
Neurofunctional changes were assessed in 6 RCTs with the
NIHSS and CNS at baseline and follow-up. In 2 studies, the
NIHSS score was available only for baseline or follow-up28,31;
1 study assessed patients with TIA only32; and 1 study did not
provide NIHSS or CNS scores.30 Independency scales were
the Barthel Index, modiﬁed Rankin Scale, Functional
e1224 Neurology | Volume 90, Number 14 | April 3, 2018 Neurology.org/N
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Independence Measure score, or Utrecht Scale for Evaluation
of Rehabilitation.
Additional individual patient data on the NIHSS or CNS
and independency scales were provided by 5
authors.24–27,33 In the combined analysis of the neuro-
functional scales (NIHSS and CNS) of these 5 studies and
1 study with original data from the publication,29 the
standardized mean diﬀerence showed overall a neurofunc-
tional improvement with CPAP with a standardized mean
diﬀerence of 0.5406 (95% CI 0.0263–1.0548). The het-
erogeneity of the studies was high with I2 = 78.9% (p =
0.0394) and a z test of 2.06 (p = 0.0394) (ﬁgure 4), and
subgroup analyses of early and delayed CPAP trials showed
nonsigniﬁcant changes. Independency scales remained
unchanged within the individual studies. An individual
correction of the neurofunctional or independency scores
for adherence was not realizable. However, a greater im-
provement in NIHSS score was mentioned in patients with
a better adherence to CPAP in 2 publications.25,33 The
results were not aﬀected by the stroke subtypes.
Neurocognitive functions, depression,
and sleepiness
Because of diﬀerent scales and heterogeneity of the reported
data, a meta-analysis of these outcomes was not possible.
Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram of study retrieval
RCT = randomized controlled trial.
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Table 1 Characteristics of the included CPAP RCTs
Study Comparator Participants, n CPAP group, n Follow-up Age, y Female, % BMI, kg/m2 CPAP use, h/night Dropouts, n (%)
Early CPAP treatment
Bravata et al,32 2010 UC 70 45 90 d CPAP 47-88 CPAP 48.9 CPAP 28.6 ± 4.1 5.6 (5.15–6.06)a CPAP 9 (20)
Control 45-88 Control 52 Control 27.8 ± 6.5 Control 5 (20)
Bravata et al,33 2011 UC 55 31 30 d CPAP 52-88 CPAP 32.3 CPAP 26.8 ± 4.3 5.10 (4.49–5.71)a CPAP 9 (29)
Control 50-94 Control 33.3 Control 29.4 ± 7.2 Control 3 (13)
Minnerup et al,25 2012 UC 50 25 8 nights CPAP 68.6 ± 10 CPAP 64 CPAP 27.8 ± 2.5 4.2 (3.79–5.61)a None
Control 63.4 ± 10.5 Control 60 Control 26.7 ± 3.1
Brown et al,31 2013 Sham 32 15 3 mo CPAP 61 (46–76) CPAP 67 CPAP 28 (23–31) CPAP 4.2 (2.6–5.5) CPAP 7 (47)
Control 74 (55–81) Control 24 Control 29 (28–32) Sham 3.5 (1.8–4.1) Sham 6 (35)
Parra et al,27,34 2011, 2015 UC 140 71 24 mo CPAP 63.7 ± 9.1 CPAP 28.1 CPAP 30.2 ± 4.6 5.3 (4.99–5.61)a None
68 mo Control 65.5 ± 9.1 Control 30.4 Control 28.8 ± 4 1 wk after stroke
Delayed CPAP treatment
Sandberg et al,30 2001 UC 63 33 28 d CPAP 78.1 ± 6.4 CPAP 54.8 CPAP 24.5 ± 4.1 4.1 (3.21–4.99)a CPAP 2 (6)
Control 6.8 ± 7.9 Control 53.6 Control 24.8 ± 4.8 Control 2 (7)
Hsu et al,29 2006 UC 30 15 6 mo CPAP 74 (73–81) CPAP 26.7 CPAP 26.8 (21–28.5) Mean 1.4 CPAP 3 (20)
8 wk Control 73 (65–77) Control 40 Control 25.1 (22.1–33.1) Median 0.16 over 8 wk Control 0 (0)
Ryan et al,26 2011 UC 48 25 4 wk CPAP 2.8 ± 12.8 CPAP 27.3 CPAP 28.8 ± 5.3 4.96 (4.32–5.60)a CPAP 3 (12)
Control 60.7 ± 10.3 Control 13.6 Control 27.3 ± 5.8 Control 1 (4)
Khot et al,28 2016 Sham 40 20 28 d CPAP 55.9 ± 12.1 CPAP 50 CPAP 31 ± 5.7 CPAP 3.9 ± 2.7 CPAP 7 (35)
Control 56.5 ± 12.1 Control 40 Control 28.5 ± 4 Sham 3.6 ± 1.8 Sham 3 (15)
Aaronson et al,24 2016 UC 36 20 2 mo CPAP 61.1 ± 8.2 CPAP 40 CPAP 28.1 ± 6.4 2.50 (1.59–3.41)a CPAP 6 (30)
4 wk Control 56.7 ± 8.8 Control 37.5 Control 25.8 ± 4.7 Control 4 (25)
Abbreviations: AHI = apnea-hypopnea index; BMI = body mass index; CPAP = continuous positive airway pressure; RCT = randomized controlled trial; UC = usual care.
Data are presented as ranges, mean ± SD, or median (interquartile range) unless otherwise indicated.
a The 95% confidence interval.
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There was an improvement in neurocognitive tests in the
intention-to-treat analyses in the CPAP group in the 2 most
recent RCTs,24,28 while there were no signiﬁcant diﬀerences
in standard cognitive screening tests in others.29,30 Three
trials assessed depressive symptoms,26,30,31 and 2 found an
improvement in favor of the CPAP treatment.26,30 Findings
on sleepiness were inconsistent: 2 RCTs, one of them starting
CPAP in the acute setting, did not ﬁnd a diﬀerence,33,34
whereas the third trial found signiﬁcant diﬀerences in favor of
CPAP.26
Figure 2 Forest plot representing the probability to drop out (random-effects model)
CI = confidence interval; CPAP = continuous
positive airway pressure; OR = odds ratio.
Figure 3 Forest plot representing the adherence to CPAP treatment in hours per night (random-effects model)
CI = confidence interval; CPAP = continuous
positive airway pressure.
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New vascular events and mortality
Two RCTs with early CPAP found no signiﬁcant diﬀerences
in the few combined vascular events (recurrent TIA, stroke,
myocardial infarction, hospitalization for congestive heart
failure, death) that were recorded within the studies, but the
trials were neither long enough nor suﬃciently powered for
this outcome.32,33 An improvement in cardiovascular survival
compared to usual care was found in a long-term follow-up
over 5 years.34 In this RCT, CPAP compared to usual care was
associated with a longer time to the next cardiovascular event
(14.9 vs 7.9 months), but there was no signiﬁcant diﬀerence in
the overall cardiovascular event–free survival, and the gener-
alizability of these ﬁndings is limited by a small sample
size.27,34
Discussion
This meta-analysis shows that adherence to CPAP treatment,
once tolerated, is acceptable in stroke survivors with SDB in
the acute and more chronic setting. The overall adherence of
study participants of 4.5 hours a night seems remarkable be-
cause compliance to CPAP is already a diﬃcult issue in the
general SDB population and is even more challenging in
neurologically impaired stroke survivors and the particularly
diﬃcult environmental circumstances of stroke units. How-
ever, this high adherence rate has to be interpreted with
caution and needs to be balanced against the fact that most of
the RCTs were designed as feasibility studies with short and
variable durations of the intervention and heterogeneous
follow-up intervals. The diﬃcult recruitment of stroke
patients and their high dropout rates in clinical trials were also
seen in the trials included in this meta-analysis, even in the
newer RCTs.35 Early dropouts were not considered for the
analysis in most RCTs, which may also bias the reported
adherence rates and lead to an overestimation. In addition, the
number of rather mildly aﬀected patients might have been
higher in the RCTs than it is to be expected in routine
practice.
CPAP treatment was judged as safe across the trials, and no
serious adverse events related to the intervention were
reported. Similar to CPAP trials in the general population,
nonserious adverse events, related to the mask, were more
frequent in the CPAP groups and would probably be ac-
ceptable if a beneﬁcial treatment eﬀect could be
demonstrated.
SDB after ischemic stroke is believed to contribute to neural
damage and a worse stroke outcome by aﬀecting the perfusion
and oxygenation of the penumbra.7,11,36 In theory, the early
application of CPAP may therefore contribute to a longer
survival of the penumbra and result in clinically and radio-
logically measurable neurologic improvements. Short-term
neuroimaging eﬀects have not been investigated suﬃciently in
the available trials, but in terms of the neurofunctional out-
comes, a recent review and meta-analysis on noninvasive
ventilator correction in patients with acute ischemic stroke
postulated a positive association of noninvasive ventilator
correction and short-term neurologic improvement.37 This
meta-analysis included only 2 small RCTs and 1 observational
study with a matched control group in the analysis of the
Figure 4 Forest plot representing SMDs and 95% CIs (random-effects model) of NIHSS and CNS
Values of the NIHSS have been inverted. CI =
confidence interval; CNS = Canadian Neu-
rological Scale; CPAP = continuous positive
airway pressure; NIHSS = NIH Stroke Scale;
SMD = standard mean difference.
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neurologic outcome, which explains the low heterogeneity but
also weakens the signiﬁcance of their ﬁndings. Our analysis
included more studies and additional individual patient data,
and the subgroup analysis of the included early treatment
initiation trials showed no signiﬁcant diﬀerence between
CPAP and the comparator. This indicates the need for a larger
sample size to evaluate whether CPAP is really beneﬁcial for
early neurologic recovery.
A delayed start of CPAP might not be able to inﬂuence the
penumbra anymore, but because SDB contributes in-
dependently to cognitive dysfunction, sleepiness, and de-
pression, a positive treatment eﬀect on these components
could lead to a better participation in the rehabilitation pro-
gram and support the recovery from stroke.36 Despite the
statistically signiﬁcant result across all 6 included trials favoring
CPAP, the subgroup analysis of neurofunctional change of the
delayed starting RCTs also remained nonsigniﬁcant.
CPAP adherence led to better neurologic outcomes in 2
RCTs, which is in line with adherence analyses performed for
the eﬀect of CPAP on blood pressure that showed treatment
results in favor of CPAP.38 Thus, an adequate adherence
might be essential for further CPAP trials in stroke survivors.
There was only 1 RCTwith a long-term follow-up over 5 years,
which showed a longer cardiovascular event–free survival with
CPAP.34 This matches the ﬁndings of the largest available
observational study in this ﬁeld, which also found a reduction of
cardiovascular events in stroke patients treated with CPAP.39
Considering data from the general population, a beneﬁcial in-
ﬂuence of CPAP on vascular prognosis could also be expected
in patients with neurologic sequelae.9,11,12 However, the
available data are not suﬃcient to conﬁrm this hypothesis.
The overall signiﬁcant positive result on the neurofunctional
outcome (ﬁgure 4) has to be interpreted with caution because
of several limitations. The analysis and comparability of the
included studies are limited by the high dropout rates and
small sample sizes, as well as a relevant heterogeneity across
the RCTs due to methodologic diﬀerences (partial blinding,
onset of treatment, follow-up duration, and outcome param-
eters) and, to a lesser, extended clinical diversity (inclusion of
AHI, TIA vs stroke). We tried to account for this by using
random-eﬀects models for our analyses, and because of the
available heterogeneous datasets, we used both NIHSS and
CNS changes to increase the sample size for the assessment of
the neurologic outcome and contacted authors for individual
patient data. Because there is no deﬁned minimal, clinically
important diﬀerence regarding the improvement in NIHSS
and CNS, a more appropriate outcome assessment would
have included the analysis of independency scales such as the
Barthel Index. A meta-analysis of these scales could not be
performed because of insuﬃcient data.
The data on CPAP treatment after stoke are promising.
However, because of the heterogeneity and limitations of the
currently available trials, the data are not suﬃcient to draw
conﬁdent evidence-based conclusions about the beneﬁcial
eﬀects on neurologic and cognitive outcomes or long-term
survival. Apart from clinical scales and neurocognitive testing,
further trials with well-predeﬁned outcome parameters should
also focus on imaging methods and include a larger number of
patients. Further RCTs are required to clarify the place of
CPAP in the treatment of SDB after stroke.
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Study question
Do existing randomized controlled trials (RCTs) support the
eﬃcacy of continuous positive airway pressure (CPAP) in
stroke patients with sleep-disordered breathing (SDB)?
Summary answer
Existing RCTs indicate that CPAP may aid neurologic re-
covery in stroke patients with SDB.
What is known and what this paper adds
Obstructive sleep apnea (OSA), which is a form of SDB and
a common comorbidity in stroke patients, can be eﬀectively
treated with CPAP in the general population, but studies in
stroke patients have yielded conﬂicting results. This meta-
analysis provides evidence supporting the eﬃcacy of CPAP in
aiding neurologic recovery in stroke patients with SDB.
Design, size, and duration
This study began with a systematic search of Medline,
Embase, and the Cochrane Library for RCTs published be-
tween January 1980 and November 2016 that compared
CPAP to either shamCPAP or usual care in patients with SDB
and either TIA or stroke. RCT bias was assessed with the
Cochrane Risk of Bias Tool.
Participants and setting
The meta-analysis examined 10 RCTs published between 2001
and 2016 with a total of 564 participants with OSA following
either TIA or stroke. In total, the CPAP, sham CPAP, and usual
care groups included 300, 37, and 227 participants. The settings
included acute care hospitals and rehabilitation units.
Primary outcomes
The primary outcome was the overall neurofunctional im-
provement with CPAP as measured with either the NIH
Stroke Scale (NIHSS) or the Canadian Stroke Scale.
Main results and the role of chance
NIHSS or Canadian Stroke Scale data were available for 6
RCTs (166 CPAP group participants; 167 control group
participants). The standardized mean diﬀerence for neuro-
functional improvement with CPAP was 0.5406 (95% conﬁ-
dence interval 0.0263–1.0548), but the heterogeneity across
studies was considerable (I2 = 78.9%; p = 0.0394).
Bias, confounding, and other reasons
for caution
The RCTs had high participant withdrawal rates and relatively
small sample sizes. Few of the RCTs had matched control
groups. Methodologic inconsistencies resulted in high het-
erogeneity. The minimum clinically important improvements
on the NIHSS and Canadian Stroke Scale are undeﬁned.
Generalizability to other populations
The RCTs might have disproportionately included patients
with mild symptoms. This would limit generalizability to
patients with severe symptoms.
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